Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Buys C$31,277.77 in Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Guillermo Torre acquired 17,240 shares of the company’s stock in a transaction dated Thursday, December 26th. The stock was acquired at an average price of C$1.81 per share, for a total transaction of C$31,277.77.

Cardiol Therapeutics Stock Performance

CRDL opened at C$1.89 on Friday. The company has a quick ratio of 6.84, a current ratio of 2.39 and a debt-to-equity ratio of 1.07. The stock’s 50 day moving average price is C$2.29 and its two-hundred day moving average price is C$2.63. The firm has a market capitalization of C$132.07 million, a P/E ratio of -4.30 and a beta of 0.70. Cardiol Therapeutics Inc. has a 12-month low of C$1.09 and a 12-month high of C$4.26.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.